Comprehensive Pharmaceutical Care and Service-Related Outcomes During Vonoprazan-Amoxicillin Dual Therapy in Elderly Patients: A Retrospective Cohort Study Authors: Hui Jiang, Mengmeng Zhang, Shuang Li, Yaqi Wang, Najing Fu, Xiwen He, Junjuan Wang Published: 2026 ABSTRACT BackgroundThis study evaluated the potential association between clinical pharmacist-led comprehensive pharmaceutical care and treatment outcomes in elderly patients receiving initial vonoprazan-amoxicillin dual therapy for Helicobacter pylori infection.MethodsIn this single-center retrospective cohort study, a total of 100 elderly patients (≥65 years) with H. pylori infection who received initial eradication therapy between May 2023 and May 2025 were included. Based on the level of pharmaceutical care provided during treatment, patients were classified into a control group (n=50, receiving standard medication counseling) or an observation group (n=50, receiving multi-stage, pharmacist-led comprehensive pharmaceutical care). Outcomes included adverse events, H. pylori eradication rate, medication adherence, and patient satisfaction.ResultsThe incidence of adverse events was lower in the observation group than in the control group (12.0% vs 30.0%, P=0.027). The H. pylori eradication rate was numerically higher in the observation group (84.0% vs 74.0%, P=0.220). Medication adherence was significantly better in the observation group than in the control group (P<0.001). Overall patient satisfaction was also higher in the observation group than in the control group (86.0% vs 60.0%, P=0.007).ConclusionComprehensive pharmaceutical care during dual therapy for H. pylori infection in elderly patients was associated with fewer adverse events and improved medication adherence and patient satisfaction. Introduction Due to the high morbidity and mortality rates of peptic ulcer disease and gastric cancer, Helicobacter pylori (Hp) infection remains a significant global public health concern.1 Although patient treatment regimens have become increasingly standardized in recent years and infection transmission has slowed, global Hp infection rates remain at approximately 50%.2,3 Studies have confirmed that eradicating Hp infection can reduce the risk of gastric cancer by approximately 40%,4 highlighting the significance of eradication therapy. Current Chinese guidelines strongly recommend 14-day bismuth-containing quadruple therapy as the first-line regimen.2 However, resistance rates for commonly used antibiotics such as clarithromycin and levofloxacin range from 20% to 40%, while metronidazole resistance rates are as high as 60% to 90%. The increasingly severe antibiotic resistance situation has directly led to declining Hp eradication rates,5 posing significant clinical challenges for Hp eradication therapy. The emergence of high-dose dual therapy, which contains only one antibiotic, has gained increasing prominence in clinical guidelines. Recent studies have confirmed the definitive efficacy of vonoprazan combined with amoxicillin for Hp eradication.6–9 However, as the amoxicillin dose increases, the risk of adverse events also rises accordingly. Common manifestations include diarrhea, nausea, vomiting, and rash; serious adverse events include allergic reactions, hepatotoxicity, Clostridioides difficile-associated diarrhea, hematological abnormalities, and interstitial nephritis. Elderly patients have different pharmacokinetic characteristics compared to younger populations, with overall decline in hepatic and renal function, resulting in prolonged half-lives of drugs metabolized by the liver and excreted by the kidneys, making them susceptible to cumulative damage. Additionally, elderly individuals often experience memory decline, attention deficits, lack of care, self-discontinuation of medication due to concerns about adverse events, and poor compliance. These factors collectively highlight the importance of implementing comprehensive pharmaceutical services tailored to this population. Specifically, such pharmacist-led services encompass multi-stage, systematic management across the treatment continuum, including baseline pharmacokinetic and comorbidity risk assessment, individualized medication counseling, proactive monitoring for adverse drug reactions, medication adherence support, and post-treatment follow-up.10,11 Previous studies have highlighted that treatment success in H. pylori eradication depends not only on the selection of effective therapeutic regimens but also on adequate medication adherence and appropriate treatment management. Low adherence has been recognized as an important contributor to eradication failure, particularly in patients receiving complex multi-drug regimens.12 Recent evidence suggests that pharmacist-led interventions, including medication education, adherence reinforcement, adverse drug reaction monitoring, and individualized medication management, may improve medication compliance, reduce treatment-related adverse events, and optimize the overall management of H. pylori eradication therapy.12,13 However, existing evidence regarding pharmacist-led pharmaceutical care in H. pylori infection remains limited, and most available studies have focused on conventional eradication regimens. Whether comprehensive pharmaceutical care provides additional clinical benefits for elderly patients receiving vonoprazan-amoxicillin dual therapy remains unclear. This population represents a particularly relevant target for pharmaceutical intervention because of age-related physiological changes, multimorbidity, polypharmacy, and increased susceptibility to medication-related problems. This retrospective cohort study aimed to systematically evaluate the clinical value of comprehensive pharmaceutical services in elderly Hp-infected patients treated with vonoprazan combined with high-dose amoxicillin. Materials and Methods Study Design and Patients This study was a single-center, retrospective cohort study based on electronic health records (EHR) and clinical pharmacy management database from the gastroenterology outpatient setting from May 2023 to May 2025. A total of 100 elderly patients (≥65 years) with confirmed Helicobacter pylori infection who were undergoing first-time eradication therapy were consecutively identified. Inclusion criteria were age ≥65 years, regardless of sex and Hp-positive (positive result on any of the following: rapid urease test during gastroscopy, histopathological examination, or 13C or 14C urea breath test), undergoing first-time Hp eradication treatment. In line with real-world clinical practice guidelines, a positive UBT result, or positive RUT/histology during endoscopy, was accepted for primary infection confirmation.14,15 Patients were then categorized into two cohorts based on the documented model of pharmaceutical care they received in their medical and pharmacy management records. Patients in control group received standard dual therapy (vonoprazan + high-dose amoxicillin) plus conventional pharmaceutical services, defined by documented routine dispensing medication counseling at the pharmacy window and basic scheduled follow-up contacts on Days 3, 14, and 1 month post-treatment. Patients in observation group received the same dual therapy plus clinical pharmacist-led comprehensive pharmaceutical care. These patients participated in the hospital’s structured pharmaceutical care program, with medical records documenting multi-stage care (including baseline risk/comorbidity assessment, proactive dynamic adverse reaction monitoring, personalized adherence guidance, and structured follow-up). Intervention for both groups included 14-day dual regimen of vonoprazan 20 mg once daily and amoxicillin 1.0 g three times daily. The allocation of care models was determined by the outpatient operational workflow during the study period: patients managed entirely through routine gastroenterology outpatient clinics received conventional care, whereas those managed through or referred to the specialized Clinical Pharmacy Consultation Clinic received comprehensive care. Interventions Eligible patients were categorized into either the comprehensive pharmaceutical care group (observation group, n=50) or the standard care group (control group, n=50) based on the type of pharmaceutical services they received during the study period. Both groups received 14-day Hp eradication dual therapy with the following regimen: vonoprazan fumarate tablets 20 mg once daily (30 minutes before breakfast); amoxicillin capsules 1.0 g three times daily (30 minutes after breakfast, lunch, and dinner). The control group received conventional pharmaceutical services, including standard oral medication instructions provided by pharmacists at drug dispensing and routine printed medication leaflets. Follow-up was conducted via scheduled telephone calls on days 3 and 14 of treatment and 1 month after treatment completion, focusing on overall treatment status, medication adherence, and self-reported adverse events without proactive digital monitoring or real-time consultation. The observation group received comprehensive pharmaceutical services. Before treatment initiation, patients underwent baseline assessments of organ function, potential drug–drug interactions, risk factors for adverse events, and medication management capability. At treatment initiation, individualized medication education was provided, including instructions on medication indications, dosing schedules, missed-dose management, and recognition of common adverse reactions. Standardized medication schedules and educational materials were delivered through a dedicated hospital-based WeChat mini-program. During the 14-day treatment period, patients received daily medication reminders through the WeChat mini-program. The platform also regularly distributed standardized adverse event questionnaires, enabling patients to actively report potential drug-related symptoms and treatment-related concerns. Reported symptoms were reviewed in a timely manner by the clinical pharmacy team, and appropriate guidance was provided according to a predefined adverse event management protocol, including recommendations for symptom management, treatment continuation, or physician consultation when necessary. After treatment completion, follow-up focused on reinforcing medication adherence, coordinating the 4-week post-treatment urea breath test, and assessing treatment satisfaction and adherence. All patients underwent a breath test at least 1 month after completing medication to determine Hp eradication rates and received pharmacist follow-up to assess medication compliance and adverse event rates. Clinical Outcomes and Outcome Assessment Helicobacter pylori eradication was the primary endpoint, defined as a negative urea breath test (13C or 14C) performed at least 4 weeks after completion of the 14-day treatment regimen, in accordance with guideline-recommended assessment timing. Secondary endpoints included incidence of adverse events (AEs) occurring during the treatment period, Medication adherence and patient satisfaction. Medication adherence was quantitatively assessed at the end of the 14-day treatment period using a combination of pill counts and patient-maintained medication logs. Adherence was calculated as the proportion of prescribed doses actually taken relative to the total number of prescribed doses. Patients were categorized into three adherence levels: high adherence, defined as taking ≥90% of prescribed doses (missing ≤1 day of medication); moderate adherence, defined as taking 80%–89% of prescribed doses (missing 2–3 days of medication); and low adherence, defined as taking <80% of prescribed doses (missing >3 days of medication or premature discontinuation of treatment). Satisfaction of patients was assessed at post-treatment follow-up using a structured questionnaire with three predefined categories (very satisfied, moderately satisfied, not satisfied). Overall satisfaction was defined as the proportion of patients reporting “very satisfied” or “moderately satisfied”. For Baseline assessments (at baseline), demographic characteristics and clinical variables, including age, sex, smoking and alcohol use, number of comorbidities, concomitant medications, liver and renal function status, and baseline gastrointestinal symptoms, were collected to ensure baseline comparability between treatment groups. For On-treatment assessments (Day 1–14): Participants were monitored for the occurrence, type, and frequency of adverse events throughout the treatment period. Safety data were collected through patient interviews and pharmacist follow-up. The control group received routine pharmaceutical care, whereas the observation group received pharmacist-led comprehensive pharmaceutical services throughout the treatment course. For the follow-up assessments: Scheduled follow-up contacts were conducted on Day 3, Day 14, and approximately 1 month after treatment completion. During follow-up, adverse events and medication adherence were systematically assessed and documented. For the Post-treatment outcome assessment (≥4 weeks after therapy): H. pylori eradication status was determined using a urea breath test. Patient satisfaction and medication adherence were assessed concurrently during pharmacist follow-up. Statistical Analysis Data analysis was performed using SPSS 27.0. Continuous data were tested for normality; normally distributed data were expressed as mean ± standard deviation, otherwise as median (lower quartile, upper quartile). To provide a comprehensive description of baseline characteristics, variables such as age are reported using both mean ± SD and median (IQR). Between-group comparisons were conducted using independent samples t-test or Mann–Whitney U-test. Categorical data were expressed as number of cases and percentage (%), with between-group comparisons using chi-square test. Ordinal categorical data were analyzed using Mann–Whitney U-test. P<0.05 was considered statistically significant. Results Baseline Characteristics A total of 100 elderly patients with Helicobacter pylori infection were included and categorized into two groups: the observation group (n=50) receiving comprehensive pharmaceutical services and the control group (n=50) receiving conventional pharmaceutical services. Baseline characteristics were comparable between groups (Table 1). Overall, patient age ranged from 65 to 93 years, with a mean age of 71.35 ± 5.05 years. The median age was 70 years (IQR: 67.8–75.0) in the observation group and 71 years (IQR: 67.0–74.3) in the control group (P=0.775). Male patients comprised 56.0% (n=28) of the observation group and 62.0% (n=31) of the control group (P=0.542). The baseline diagnostic methods used for H. pylori confirmation were comparable between the two groups (P=0.424). No patient was diagnosed by RUT. In the observation group, 80% (n=40) of patients were diagnosed via urea breath test, and 20% (n=10) via histopathological examination. In the control group, 86% (n=43) of patients were diagnosed by UBT, and 14% (n=7) by histology.Table 1Baseline Characteristics of Elderly H. Pylori-Infected PatientsCharacteristicObservation (n = 50)Control (n = 50)P ValueAge, years (median, IQR)70 (67.8, 75.0)71 (67.0, 74.3)0.775aMale sex, n (%)28 (56.0%)31 (62.0%)0.542bDiagnostic method, n (%)0.424bUrea breath test40 (80.0%)43 (86.0%)Histopathology10 (20.0%)7 (14.0%)Current smoker, n (%)13 (26.0%)15 (30.0%)0.656bAlcohol use, n (%)7 (14.0%)7 (14.0%)1.000bNumber of comorbid diseases (median, IQR)5.5 (2.8, 10.3)6.0 (2.8, 10.3)0.895aTaking ≥1 other medications, n (%)47 (94.0%)46 (92.0%)0.695bAbnormal liver function, n (%)18 (36.0%)15 (30.0%)0.523bAbnormal renal function, n (%)15 (30.0%)15 (30.0%)1.000bMain GI symptom0.464b Heartburn/reflux, n (%)17 (34.0%)14 (28.0%) Abdominal pain, n (%)6 (12.0%)5 (10.0%) Discomfort, n (%)9 (18.0%)5 (10.0%) Bloating, n (%)3 (6.0%)7 (14.0%) Other, n (%)15 (30.0%)19 (38.0%)Notes: a P value by Mann–Whitney U-test; b P value by chi-square test.Abbreviations: GI, gastrointestinal; IQR, interquartile range. Table 1Baseline Characteristics of Elderly H. Pylori-Infected PatientsCharacteristicObservation (n = 50)Control (n = 50)P ValueAge, years (median, IQR)70 (67.8, 75.0)71 (67.0, 74.3)0.775aMale sex, n (%)28 (56.0%)31 (62.0%)0.542bDiagnostic method, n (%)0.424bUrea breath test40 (80.0%)43 (86.0%)Histopathology10 (20.0%)7 (14.0%)Current smoker, n (%)13 (26.0%)15 (30.0%)0.656bAlcohol use, n (%)7 (14.0%)7 (14.0%)1.000bNumber of comorbid diseases (median, IQR)5.5 (2.8, 10.3)6.0 (2.8, 10.3)0.895aTaking ≥1 other medications, n (%)47 (94.0%)46 (92.0%)0.695bAbnormal liver function, n (%)18 (36.0%)15 (30.0%)0.523bAbnormal renal function, n (%)15 (30.0%)15 (30.0%)1.000bMain GI symptom0.464b Heartburn/reflux, n (%)17 (34.0%)14 (28.0%) Abdominal pain, n (%)6 (12.0%)5 (10.0%) Discomfort, n (%)9 (18.0%)5 (10.0%) Bloating, n (%)3 (6.0%)7 (14.0%) Other, n (%)15 (30.0%)19 (38.0%)Notes: a P value by Mann–Whitney U-test; b P value by chi-square test.Abbreviations: GI, gastrointestinal; IQR, interquartile range. Baseline Characteristics of Elderly H. Pylori-Infected Patients Notes: a P value by Mann–Whitney U-test; b P value by chi-square test. Abbreviations: GI, gastrointestinal; IQR, interquartile range. Current smoking status was reported by 26.0% (n=13) and 30.0% (n=15) of patients, respectively (P=0.656), while alcohol use was identical at 14.0% (n=7) in both groups (P=1.000). The median number of comorbid diseases was 5.5 (IQR: 2.8–10.3) in the observation group and 6.0 (IQR: 2.8–10.3) in the control group (P=0.895). The proportion of patients taking one or more concomitant medications was 94.0% (n=47) and 92.0% (n=46), respectively (P=0.695). Abnormal liver function was present in 36.0% (n=18) versus 30.0% (n=15) of patients (P=0.523), and abnormal renal function was observed in 30.0% (n=15) in both groups (P=1.000). The distribution of main gastrointestinal symptoms did not differ significantly between groups (P=0.464). No statistically significant differences were observed in any baseline characteristic (all P>0.05). Comparison of Hp Eradication Rates and Safety The incidence of adverse events during therapy is presented in Table 2. In the observation group, adverse events included constipation (4.0%, n=2), diarrhea (2.0%, n=1), and abdominal bloating (6.0%, n=3), with no cases of nausea reported. In the control group, adverse events included constipation (2.0%, n=1), nausea (4.0%, n=2), diarrhea (8.0%, n=4), and abdominal bloating (16.0%, n=8). The overall incidence of any adverse drug reaction was significantly lower in the observation group (12.0%, n=6) compared to the control group (30.0%, n=15; P=0.027). The H. pylori eradication rate was 84.0% (42/50) in the observation group and 74.0% (37/50) in the control group. Although numerically higher in the observation group, this difference did not reach statistical significance (P=0.220).Table 2Incidence of Adverse Events During Therapy and H. Pylori Eradication RatesAdverse eventsObservation (n = 50)Control (n = 50)P ValueEradication rate, n (%)42 (84.0%)37 (74.0%)0.220aAny AE, n (%)6 (12.0%)15 (30.0%)0.027aConstipation, n (%)2 (4.0%)1 (2.0%)–bNausea, n (%)0 (0%)2 (4.0%)–bDiarrhea, n (%)1 (2.0%)4 (8.0%)–bAbdominal bloating, n (%)3 (6.0%)8 (16.0%)–bNotes: a, P value by chi-square test; b, Chi-square test was not performed due to low expected cell frequencies.Abbreviation: AE, adverse event. Table 2Incidence of Adverse Events During Therapy and H. Pylori Eradication RatesAdverse eventsObservation (n = 50)Control (n = 50)P ValueEradication rate, n (%)42 (84.0%)37 (74.0%)0.220aAny AE, n (%)6 (12.0%)15 (30.0%)0.027aConstipation, n (%)2 (4.0%)1 (2.0%)–bNausea, n (%)0 (0%)2 (4.0%)–bDiarrhea, n (%)1 (2.0%)4 (8.0%)–bAbdominal bloating, n (%)3 (6.0%)8 (16.0%)–bNotes: a, P value by chi-square test; b, Chi-square test was not performed due to low expected cell frequencies.Abbreviation: AE, adverse event. Incidence of Adverse Events During Therapy and H. Pylori Eradication Rates Notes: a, P value by chi-square test; b, Chi-square test was not performed due to low expected cell frequencies. Abbreviation: AE, adverse event. Comparison of Medication Compliance, Satisfaction Survey Medication adherence differed significantly between groups (Table 3). In the observation group, 78.0% (n=39) of patients demonstrated high adherence, 8.0% (n=4) moderate adherence, and 14.0% (n=7) low adherence. In contrast, the control group showed 42.0% (n=21) high adherence, 32.0% (n=16) moderate adherence, and 26.0% (n=13) low adherence. The overall distribution of adherence levels was significantly different between groups (P<0.001, Mann–Whitney U-test).Table 3Comparison of Medication Adherence Between GroupsObservation (n = 50)Control (n = 50)P ValueAdherence categorya<0.001bHigh adherence39 (78.0%)21 (42.0%)Moderate adherence4 (8.0%)16 (32.0%)Low adherence7 (14.0%)13 (26.0%)Notes: a, high adherence, defined as taking ≥90% of prescribed doses (missing ≤1 day of medication); moderate adherence, defined as taking 80%–89% of prescribed doses (missing 2–3 days of medication); low adherence, defined as taking <80% of prescribed doses (missing >3 days of medication or premature discontinuation of treatment); b, P value by Mann–Whitney U-test. Table 3Comparison of Medication Adherence Between GroupsObservation (n = 50)Control (n = 50)P ValueAdherence categorya<0.001bHigh adherence39 (78.0%)21 (42.0%)Moderate adherence4 (8.0%)16 (32.0%)Low adherence7 (14.0%)13 (26.0%)Notes: a, high adherence, defined as taking ≥90% of prescribed doses (missing ≤1 day of medication); moderate adherence, defined as taking 80%–89% of prescribed doses (missing 2–3 days of medication); low adherence, defined as taking <80% of prescribed doses (missing >3 days of medication or premature discontinuation of treatment); b, P value by Mann–Whitney U-test. Comparison of Medication Adherence Between Groups Notes: a, high adherence, defined as taking ≥90% of prescribed doses (missing ≤1 day of medication); moderate adherence, defined as taking 80%–89% of prescribed doses (missing 2–3 days of medication); low adherence, defined as taking <80% of prescribed doses (missing >3 days of medication or premature discontinuation of treatment); b, P value by Mann–Whitney U-test. Patient satisfaction with treatment is summarized in Table 4. In the observation group, 64.0% (n=32) of patients reported being very satisfied, 22.0% (n=11) moderately satisfied, and 14.0% (n=7) not satisfied. In the control group, 42.0% (n=21) were very satisfied, 18.0% (n=9) moderately satisfied, and 40.0% (n=20) not satisfied. The overall satisfaction rate (very satisfied + moderately satisfied) was 86.0% (n=43) in the observation group compared to 60.0% (n=30) in the control group. The distribution of satisfaction ratings differed significantly between groups (P=0.007, Mann–Whitney U-test).Table 4Patient Satisfaction with Treatment in the Two GroupsObservation (n = 50)Control (n = 50)P ValueSatisfaction rating0.007Very satisfied32 (64.0%)21 (42.0%)Moderately satisfied11 (22.0%)9 (18.0%)Not satisfied7 (14.0%)20 (40.0%)Overall satisfieda43 (86.0%)30 (60.0%)Notes: a, Overall satisfied = Very satisfied + Moderately satisfied. Table 4Patient Satisfaction with Treatment in the Two GroupsObservation (n = 50)Control (n = 50)P ValueSatisfaction rating0.007Very satisfied32 (64.0%)21 (42.0%)Moderately satisfied11 (22.0%)9 (18.0%)Not satisfied7 (14.0%)20 (40.0%)Overall satisfieda43 (86.0%)30 (60.0%)Notes: a, Overall satisfied = Very satisfied + Moderately satisfied. Patient Satisfaction with Treatment in the Two Groups Notes: a, Overall satisfied = Very satisfied + Moderately satisfied. Discussion In recent years, vonoprazan, as a novel potassium-competitive acid blocker (P-CAB), combined with high-dose amoxicillin has demonstrated significant advantages in treating Hp infection in elderly patients.16 Multiple clinical studies have confirmed that this regimen can achieve eradication rates of 85%–95% in elderly patients, significantly superior to traditional PPI-based triple therapy. However, due to characteristics of elderly Hp-infected patients such as reduced gastric acid secretion, complex medication regimens, and difficulties in compliance management,17,18 controversies remain regarding the safety and efficacy of drug therapy. Comprehensive pharmaceutical services aim to cover the entire process of drug therapy, improving treatment efficiency and patient quality of life through comprehensive and continuous pharmacy-related services.13 In this retrospective cohort study, we investigated the association between clinical pharmacist-led pharmaceutical care interventions and improved outcomes among elderly patients receiving initial vonoprazan-amoxicillin dual therapy for Helicobacter pylori infection. Results showed that the Hp eradication rate in the observation group was slightly higher than the control group, but the difference was not statistically significant. However, comprehensive pharmaceutical services showed potential effect in reducing adverse events and improving patient satisfaction and medication compliance. Currently, dual therapy using vonoprazan combined with high-dose amoxicillin as a standard Hp eradication regimen has reached a certain efficacy “ceiling”.1,19,20 Against a backdrop of generally high baseline medical quality, the added value of pharmaceutical services may be difficult to demonstrate as significant differences in the hard endpoint of eradication rate with the current sample size. Furthermore, the main reasons for eradication failure may be more related to inherent factors such as bacterial resistance and pharmacogenomic variations in drug metabolism,21 which pharmaceutical services cannot directly modify in the short term. Nevertheless, the eradication rates observed in this study remained numerically high, indicating that pharmaceutical service intervention had the potential to improve eradication efficacy without negatively affecting overall outcomes. In this study, the implementation of comprehensive pharmaceutical services was associated with lower incidence of drug therapy-related adverse events, with rates in the observation group remaining low at 12.00%, representing a statistically significant improvement over controls. This result demonstrated the value of pharmaceutical services on ensuring medication safety.22 By systematically educating patients about medication beforehand, detailing possible side effects and corresponding coping strategies, and through proactive follow-up and continuous monitoring, patients can receive professional guidance and take effective measures promptly when mild discomfort occurs, thereby preventing symptom exacerbation or treatment interruption. This model not only embodies the “patient-centered” service philosophy but also has the potential to reduce additional healthcare resource consumption caused by adverse events. Correspondingly, patient satisfaction and medication compliance were significantly improved. The satisfaction rate in the observation group was 86.00%, with high adherence accounting for 78.00%, significantly higher than the control group (P<0.05), which is closely related to effective adverse event management. Studies have shown23,24 that improving patient compliance and closely monitoring adverse events can reduce the risk of various diseases. When patients feel continuously cared for and receive timely professional answers to their concerns, their trust in the entire medical team is further enhanced, and their treatment experience is significantly improved. The communication channels and management models established by comprehensive pharmaceutical services provide a solid foundation for maintaining high long-term compliance, which may further improve final outcomes in future studies with larger samples or longer observation periods. Several limitations of this study warrant consideration. First, as a single-center retrospective cohort study based on electronic health records and pharmacy management databases, inherent selection bias and residual confounding cannot be completely excluded. Second, the allocation of pharmaceutical care models was determined by routine outpatient workflows: patients managed in standard gastroenterology clinics received conventional care, whereas those referred to or opting for the Clinical Pharmacy Consultation Clinic received comprehensive care, potentially introducing allocation bias. Third, the relatively small sample size without formal sample size calculation may have limited the power to detect modest differences in secondary outcomes, such as numerical variations in eradication rates. Fourth, adherence and patient satisfaction were assessed using institutionally developed questionnaires and self-reported logs rather than validated standardized instruments. Moreover, because clinical pharmacists delivering the intervention also performed follow-up assessments, these subjective outcomes may have been affected by reporting or observer bias. Although pill counts were used to support adherence assessment, the absence of independent blinded assessors remains a limitation. Finally, although all patients were treatment-naïve for H. pylori eradication, prior antibiotic and the acid-suppressive exposure for unrelated infections was not routinely documented, representing a potential unmeasured confounder. Future prospective, multicenter randomized controlled trials with larger sample sizes are warranted to validate these findings. Conclusion In conclusion, within the inherent constraints of a retrospective cohort design, clinical pharmacist-led comprehensive pharmaceutical care was associated with a reduced incidence of adverse drug reactions, as well as improved medication adherence and patient satisfaction during dual therapy for H. pylori infection in elderly patients. While these findings highlight the practical value of continuous pharmaceutical care, no significant improvement in eradication rate was observed. Therefore, the observed clinical benefits warrant confirmation in future multi-center, prospective, randomized, blinded trials before definitive conclusions can be drawn.